Texture and Color Enhancement Imaging for the Kyoto Classification of Gastritis: Evaluation of Visibility and Color Differences

基于京都分类的胃炎纹理和色彩增强成像:可见性和颜色差异的评估

阅读:1

Abstract

INTRODUCTION: The Kyoto Classification of Gastritis enables endoscopic assessment of Helicobacter pylori (H. pylori) infection status and gastric cancer risk. Initially developed for image-enhanced endoscopy, texture and color enhancement imaging (TXI) allows us to easily distinguish differences in mucosal structure and color. The aim of this study was to evaluate the use of TXI in the visibility of endoscopic findings of gastritis. METHODS: This was a retrospective analysis using prospectively collected endoscopic data from a prospective, single-center study, in which 220 patients undergoing esophagogastroduodenoscopy were enrolled. Endoscopic images were obtained using both white light imaging (WLI) and TXI (TXI-1 and TXI-2). Ten endoscopists (five experts and five trainees) independently evaluated 52 matched image sets, scoring visibility on a 5-point scale. Inter-rater reliability was assessed using intraclass correlation coefficients. Objective color analysis using the CIE L*a*b* color space and ΔE* values was also performed for map-like redness. RESULTS: TXI-1 improved visibility for diffuse redness, spotty redness, map-like redness, patchy redness, atrophic border, red streak, and the regular arrangement of collecting venules. Visibility of intestinal metaplasia was also enhanced by TXI-1, although to a lesser extent than other findings. TXI-1 demonstrated "moderate" to "substantial" inter-rater reliability. Objective colorimetric analysis confirmed significantly greater ΔE* values with TXI-1 versus WLI for map-like redness. CONCLUSION: TXI-1 enhances the visibility of key endoscopic features of H. pylori-associated gastritis. TXI-1 may serve as a useful tool for endoscopic assessment of H. pylori-associated gastritis. TRIAL REGISTRATION: The study protocol was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000045323).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。